Researchers tested the C-Scan system version three in 31 patients at multiple overseas centers. The system detects polyps in patients with unprepared colons.
Here’s what you should know:
1. The device had 76 percent sensitivity and 80 percent specificity.
2. Independent investigators performed confirmatory colonoscopies to crosscheck the results.
3. C-Scan’s newest version included better imaging density, 2D/3D testing and a motility analysis algorithm.
Final results from the trial are expected in the second quarter of 2019.
Check-Cap CEO Alex Ovadia said, “We believe that the encouraging interim results from our ongoing post CE approval study demonstrate a significant progress in the clinical performance of C-Scan compared with previously communicated CE study results for our patient-friendly, and preparation-free colon-cancer screening device.”
Check-Cap will initiate a U.S.-based pilot trial in the fourth quarter of 2018.
More articles on gastroenterology:
ASC supply chain tip of the day: Dedicate a supply chain staff
4 insights on outpatient joint replacement surgery from Dr. Ravi Bashyal
Jim Brown appointed CEO of new HCA Gulf Coast acquisition North Cypress Medical Center — 5 insights
